Drug intelligence / Profile preview

meropenem + trimethoprim-sulfamethoxazole

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination antibiotic therapy consisting of meropenem (a carbapenem antibiotic) and trimethoprim-sulfamethoxazole (a fixed-dose combination antibiotic). The combination is used to treat various bacterial infections, particularly those caused by multi-drug resistant organisms. Meropenem works by penetrating bacterial cells and interfering with cell wall synthesis, while trimethoprim-sulfamethoxazole acts by inhibiting successive steps in the bacterial folate synthesis pathway, creating a synergistic effect.

Other names: meropenem + TMP-SMX

Targets

DHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on meropenem + trimethoprim-sulfamethoxazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meropenem + trimethoprim-sulfamethoxazole.

Explore the full profile